drugset
drugset / Trial / NCT04809116

Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

NCT04809116 ↗

Phase 4 Withdrawn Baylor College of Medicine ACADIA Pharmaceuticals Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a proof-of-concept, open-label trial of pimavanserin 34mg at bedtime for 6 weeks in Veterans with insomnia and Posttraumatic Stress Disorder.

Timeline

Start
2022-12-15
Primary completion
2023-12-15
Completion
2023-12-15

Outcome

Outcome not reported

Stopped (Business): “Received alternative sources of funding.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimavanserin Small molecule 34 mg —

Indications

insomnia post-traumatic stress disorder